Who are Tedizolid (BAY119-2631)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Linezolid (L), Azithromycin Ophthalmic Solution, 1%, Azithromycin Oral Product, Erythromycin, Azithromycin , Clarithromycin, Oral Suspension Tedizolid Phosphate, Tedizolid PO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tedizolid-bay119-2631.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Tedizolid (BAY119-2631) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tedizolid (BAY119-2631) (Tedizolid (BAY119-2631)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: oxazolidinone antibiotic. Area: Infectious Disease.

phase 3 oxazolidinone antibiotic 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Tedizolid (BAY119-2631) (Tedizolid (BAY119-2631)) — Bayer. Tedizolid is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tedizolid (BAY119-2631) TARGET	Tedizolid (BAY119-2631)	Bayer	phase 3	oxazolidinone antibiotic	50S ribosomal subunit
Linezolid (L)	Linezolid (L)	Shenzhen Third People's Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Ophthalmic Solution, 1%	Azithromycin Ophthalmic Solution, 1%	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Oral Product	Azithromycin Oral Product	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Erythromycin, Azithromycin , Clarithromycin	Erythromycin, Azithromycin , Clarithromycin	Baqiyatallah Medical Sciences University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Oral Suspension Tedizolid Phosphate	Oral Suspension Tedizolid Phosphate	Merck Sharp & Dohme LLC	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Tedizolid PO	Tedizolid PO	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (oxazolidinone antibiotic class)

Bayer · 1 drug in this class
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tedizolid (BAY119-2631) — Competitive Intelligence Brief. https://druglandscape.com/ci/tedizolid-bay119-2631. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab